» Articles » PMID: 33945115

Impact of Intraoperative Magnetic Resonance Imaging on Gross Total Resection, Extent of Resection, and Residual Tumor Volume in Pituitary Surgery: Systematic Review and Meta-analysis

Overview
Journal Pituitary
Specialty Endocrinology
Date 2021 May 4
PMID 33945115
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Residual tumor tissue after pituitary adenoma surgery, is linked with additional morbidity and mortality. Intraoperative magnetic resonance imaging (ioMRI) could improve resection. We aim to assess the improvement in gross total resection (GTR), extent of resection (EOR), and residual tumor volume (RV) achieved using ioMRI.

Methods: A systematic review was carried out on PubMed/MEDLINE to identify any studies reporting intra- and postoperative (1) GTR, (2) EOR, or (3) RV in patients who underwent resection of pituitary adenomas with ioMRI. Random effects meta-analysis of the rate of improvement after ioMRI for these three surgical outcomes was intended.

Results: Among 34 included studies (2130 patients), the proportion of patients with conversion to GTR (∆GTR) after ioMRI was 0.19 (95% CI 0.15-0.23). Mean ∆EOR was + 9.07% after ioMRI. Mean ∆RV was 0.784 cm. For endoscopically treated patients, ∆GTR was 0.17 (95% CI 0.09-0.25), while microscopic ∆GTR was 0.19 (95% CI 0.15-0.23). Low-field ioMRI studies demonstrated a ∆GTR of 0.19 (95% CI 0.11-0.28), while high-field and ultra-high-field ioMRI demonstrated a ∆GTR of 0.19 (95% CI 0.15-0.24) and 0.20 (95% CI 0.13-0.28), respectively.

Conclusions: Our meta-analysis demonstrates that around one fifth of patients undergoing pituitary adenoma resection convert from non-GTR to GTR after the use of ioMRI. EOR and RV can also be improved to a certain extent using ioMRI. Endoscopic versus microscopic technique or field strength does not appear to alter the impact of ioMRI. Statistical heterogeneity was high, indicating that the improvement in surgical results due to ioMRI varies considerably by center.

Citing Articles

Surgical management of skull base chordomas and chondrosarcomas: insights from a national cohort study.

Glancz L, Hannan C, Vyziotis A, Potter G, Siripurapu R, Bhalla R BMJ Oncol. 2025; 3(1):e000386.

PMID: 39886144 PMC: 11347697. DOI: 10.1136/bmjonc-2024-000386.


Suprasellar Anterior-Posterior Diameter Optimizes the Use of Intraoperative MRI in Patients Undergoing Endoscopic Pituitary Surgery.

Hannan C, Daousi C, Radon M, Gilkes C Oper Neurosurg (Hagerstown). 2024; 28(4):487-495.

PMID: 39162407 PMC: 11893087. DOI: 10.1227/ons.0000000000001319.


Neuronavigation-assisted pituitary neuroendocrine tumor resection: a systematic review and meta-analysis.

Huang Y, Qin L, Lv H, Lv S, Lu Y Quant Imaging Med Surg. 2024; 14(7):5012-5027.

PMID: 39022256 PMC: 11250324. DOI: 10.21037/qims-23-1570.


Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience.

Mirzayeva L, Ucar M, Kaymaz A, Temel E J Neurooncol. 2024; 168(2):249-257.

PMID: 38568377 PMC: 11147832. DOI: 10.1007/s11060-024-04660-z.


Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.

Korbonits M, Blair J, Boguslawska A, Ayuk J, Davies J, Druce M Nat Rev Endocrinol. 2024; 20(5):278-289.

PMID: 38336897 DOI: 10.1038/s41574-023-00948-8.


References
1.
Soneru C, Riley C, Hoffman K, Tabaee A, Schwartz T . Intra-operative MRI vs endoscopy in achieving gross total resection of pituitary adenomas: a systematic review. Acta Neurochir (Wien). 2019; 161(8):1683-1698. DOI: 10.1007/s00701-019-03955-9. View

2.
Fahlbusch R, Keller B, Ganslandt O, Kreutzer J, Nimsky C . Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol. 2005; 153(2):239-48. DOI: 10.1530/eje.1.01970. View

3.
Bohinski R, Warnick R, Gaskill-Shipley M, Zuccarello M, van Loveren H, Kormos D . Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery. 2002; 49(5):1133-43; discussion 1143-4. DOI: 10.1097/00006123-200111000-00023. View

4.
Molitch M . Management of medically refractory prolactinoma. J Neurooncol. 2013; 117(3):421-8. DOI: 10.1007/s11060-013-1270-8. View

5.
Gohla G, Bender B, Tatagiba M, Honegger J, Ernemann U, Roder C . Identification of tumor residuals in pituitary adenoma surgery with intraoperative MRI: do we need gadolinium?. Neurosurg Rev. 2019; 43(6):1623-1629. DOI: 10.1007/s10143-019-01202-4. View